Analysts Offer Predictions for TNYA Q1 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Analysts at William Blair issued their Q1 2025 earnings per share estimates for Tenaya Therapeutics in a report released on Monday, March 10th. William Blair analyst S. Corwin expects that the company will earn ($0.15) per share for the quarter. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. William Blair also issued estimates for Tenaya Therapeutics’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.64) EPS.

TNYA has been the topic of a number of other research reports. Chardan Capital cut their price target on shares of Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday. HC Wainwright cut their price objective on shares of Tenaya Therapeutics from $18.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday. Morgan Stanley lowered their target price on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Canaccord Genuity Group lowered their target price on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Tenaya Therapeutics has a consensus rating of “Buy” and an average target price of $6.25.

Tenaya Therapeutics Trading Up 4.3 %

Shares of TNYA opened at $0.70 on Thursday. The stock has a market capitalization of $55.37 million, a P/E ratio of -0.49 and a beta of 2.83. The firm’s fifty day simple moving average is $1.06 and its two-hundred day simple moving average is $1.82. Tenaya Therapeutics has a 12 month low of $0.39 and a 12 month high of $5.39.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Woodline Partners LP bought a new position in Tenaya Therapeutics in the 4th quarter valued at $28,000. Trustees of Columbia University in the City of New York bought a new position in Tenaya Therapeutics in the 4th quarter valued at $417,000. Nuveen Asset Management LLC boosted its holdings in Tenaya Therapeutics by 25.2% in the 4th quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company’s stock valued at $494,000 after purchasing an additional 69,377 shares during the period. Ground Swell Capital LLC bought a new position in Tenaya Therapeutics in the 4th quarter valued at $32,000. Finally, Deutsche Bank AG boosted its holdings in Tenaya Therapeutics by 304.1% in the 4th quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock valued at $185,000 after purchasing an additional 97,318 shares during the period. 90.54% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was purchased at an average cost of $0.70 per share, with a total value of $24,999,998.80. Following the acquisition, the insider now directly owns 49,313,559 shares in the company, valued at approximately $34,519,491.30. This trade represents a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 19,621 shares of company stock valued at $10,595. Company insiders own 32.76% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.